Poxel (POXEL) Q3 2026 TU earnings summary

Executive summary

• Q3 2026 consolidated revenue was €1,951k; 9M revenue reached €4,453k, driven by TWYMEEG royalties in Japan.

• TWYMEEG net sales exceeded the JPY 5bn threshold in Sumitomo Pharma FY2026 H1, raising the royalty rate from 8% to 10% retroactively for FY2026.

Financial highlights

• Q3 revenue was €1,951k vs €1,292k in Q3 2025; 9M revenue was €4,453k vs €3,608k in 9M 2025.

• Q3 revenue included €1,629k in royalties and a €322k retroactive Q2 royalty adjustment; 9M included €4,131k in royalties and €322k in adjustments.

• Consolidated cash and cash equivalents were €388k at September 30, 2026, vs €1,510k at Q2 2026 and €245k at Q1 2026.

Outlook and guidance

• Sumitomo Pharma expects FY2026 TWYMEEG net sales to exceed JPY 10bn; the milestone would trigger a JPY 1bn bonus and increase royalties from 10% to 12%.

• Based on Sumitomo Pharma projections, 12% royalties are expected on TWYMEEG Japan net sales during its FY2026, which runs April 2026–March 2027.